Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Stomach Neoplasms × Paclitaxel × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 120 Observational 6 Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1 Prostatic Neoplasms 1 Lung Neoplasms 1

Interventions

Ramucirumab 2 ulixertinib 1 Proton Pump Inhibitors 1 Paclitaxel 1 Hydrocortisone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02307812 2025-01-09

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Eli Lilly and Company

Approved for marketing

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡